Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy. Kuruvilla J, Modi D, Santoro A, Paszkiewicz-Kozik E, et al. Leuk Lymphoma 2025 Jun 23:1-10. doi: 10.1080/10428194.2025.2502805.

Read + Share

Amedeo Smart

Independent Medical Education

Kuruvilla J, Modi D, Santoro A, Paszkiewicz-Kozik E, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy. Leuk Lymphoma 2025 Jun 23:1-10. doi: 10.1080/10428194.2025.2502805.
PMID: 40548833